#5 - BeiGene Ltd (NASDAQ:BGNE)
BeiGene Ltd (NASDAQ: BGNE) - Lest you think the only profit to be found in China stocks exists in the tech sector, we give you BeiGene Ltd. BeiGene is a familiar name in oncology circles and is the dominant player in the Chinese oncology market. One of the reasons their stock is drawing attention is the projected release of two new treatments, known as BTK inhibitors. These represent the leading edge of cancer research and are showing promise in shrinking or eliminating some B cell tumors. Adding to analysts’ enthusiasm, the company is projected to move another drug, Zanubrutinib, out of clinical trials this year.
BeiGene posted mixed second-quarter results. The company hit on their top line with revenues growing to $52.8 million, but missing on their adjusted earnings per share (EPS) that came in at -$2.92. Analysts were estimating an EPS of -$2.06. Despite the announcement, the company picked up a series of Buy ratings. One of those was from Top Maxim Group analyst Jason McCarthy who is projecting a $225 stock price target, up about 46% from the stock's current price. BeiGene’s valuation has increased significantly in the past year and now sits at approximately $9 billion.
About BeiGene
BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.
Read More - Current Price
- $0.00
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 6 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $253.69
